PMI (NYSEAMERICAN:PMI) Rating Increased to Hold at Zacks Research

PMI (NYSEAMERICAN:PMI) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Separately, HC Wainwright began coverage on shares of PMI in a research report on Monday. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, PMI currently has an average rating of “Hold”.

PMI Trading Down 3.7%

PMI stock opened at $0.15 on Tuesday. The firm has a 50 day simple moving average of $0.78. PMI has a 12 month low of $0.13 and a 12 month high of $13.68. The company has a current ratio of 0.75, a quick ratio of 0.72 and a debt-to-equity ratio of 0.01.

PMI (NYSEAMERICAN:PMI) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $1.15 million for the quarter. As a group, analysts predict that PMI will post -0.17 EPS for the current fiscal year.

Key PMI News

Here are the key news stories impacting PMI this week:

• Neutral Sentiment: HC Wainwright reiterated a Neutral stance on PMI while publishing updated estimates across 2026 and 2027, including projected losses in every period and full-year EPS of ($0.17) for FY2026 and ($0.09) for FY2027. PMI analyst coverage
• Neutral Sentiment: The most recent quarterly results also showed PMI remained unprofitable, with the company posting ($0.10) EPS on $1.15 million in revenue, reinforcing concerns about near-term profitability. PMI earnings results
• Negative Sentiment: Multiple analyst forecasts for the next several quarters point to continued losses, which can weigh on investor sentiment and keep pressure on the stock. PMI earnings estimates

PMI Company Profile

Picard Medical Inc is a medical technology company which manufactures and sells the only total artificial heart. Picard Medical Inc is based in TUCSON, Ariz.